{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:07Z","timestamp":1789610887544,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Malaysia Ministry of Higher Education","doi-asserted-by":"publisher","award":["FRGS\/1\/2023\/SKK10\/USM\/02\/16"],"award-info":[{"award-number":["FRGS\/1\/2023\/SKK10\/USM\/02\/16"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105002","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:42:20Z","timestamp":1762299740000},"page":"105002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Current progress in the elucidation of Acute Myeloid Leukemia (AML) immune landscapes"],"prefix":"10.1016","volume":"217","author":[{"given":"Adam","family":"Azlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norashikin","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Rifqi","family":"Rafsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheswaran","family":"Solayappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mot Yee","family":"Yik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Saifulaman Mohamed","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narazah Mohd","family":"Yusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Jairaj","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib1","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1038\/s41598-024-58689-1","article-title":"SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia","volume":"14","author":"\u00c5backa","year":"2024","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105002_bib2","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cells11142249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"issue":"July","key":"10.1016\/j.critrevonc.2025.105002_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","article-title":"Immunoprofiling of leukemic stem Cells CD34+\/CD38\u2212\/CD123+ delineate FLT3\/ITD-positive clones","volume":"9","author":"Al-Mawali","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib4","article-title":"491 Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications","volume":"10","author":"An","year":"2022","journal-title":"Regul. Young.. Invest. Award Abstr. J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41375-022-01798-5","article-title":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing P38 MAPK signaling","volume":"37","author":"Anderson","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 Expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib7","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib9","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated car t therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat. Med."},{"issue":"December","key":"10.1016\/j.critrevonc.2025.105002_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exphem.2020.09.189","article-title":"Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy","volume":"92","author":"Boila","year":"2020","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105002_bib11","article-title":"EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene","author":"Buteyn","year":"2024","journal-title":"Fusion. \u201d bioRxiv June 25 2024. 05. 14. 594150"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/cr.2011.196","article-title":"Immunosuppressive exosomes from TGF-\u03921 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells","volume":"22","author":"Cai","year":"2012","journal-title":"Cell Res."},{"issue":"August","key":"10.1016\/j.critrevonc.2025.105002_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105002_bib14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/leu.2010.149","article-title":"Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome","volume":"24","author":"Carlsten","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105002_bib15","doi-asserted-by":"crossref","unstructured":"Charrot, Sarah, Jennifer Ball, Findlay Copley, et al. 2023. \u201cP1253: REDUCED EXPRESSION OF THE CHEMOKINES CXCL2, CXCL3 AND CXCL8 PROVIDES A POTENTIAL MECHANISM PROMOTING IMMUNE EVASION FACILITATING AML RELAPSE FOLLOWING ALLOGENEIC HSCT.\u201d HemaSphere 7 (Suppl): e0435780. https:\/\/doi.org\/10.1097\/01.HS9.0000971900.04357.80.","DOI":"10.1097\/01.HS9.0000971900.04357.80"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib16","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms25042150","article-title":"Minimal residual disease in acute myeloid leukemia: old and new concepts","volume":"25","author":"Chea","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7718","key":"10.1016\/j.critrevonc.2025.105002_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with Anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"issue":"September","key":"10.1016\/j.critrevonc.2025.105002_bib18","doi-asserted-by":"crossref","first-page":"S605","DOI":"10.1016\/j.annonc.2024.08.875","article-title":"824P FLT3-ITD induces immune escape in AML via up-regulating CD47 expression and decreased phagpcytic ability of macrophages","volume":"35","author":"Chen","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","article-title":"The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: from biology to therapeutic targeting","volume":"8","author":"Chen","year":"2022","journal-title":"Cell Death Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib20","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.34184\/kssb.2023.11.4.55","article-title":"Crystal structure of the fab fragment of gemtuzumab ozogamicin, the first approved antibody-drug conjugate for induction therapy of AML","volume":"11","author":"Choi","year":"2023","journal-title":"BioDesign"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105002_bib22","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3324\/haematol.2025.287394","article-title":"The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemia","volume":"110","author":"Cruz-Rodriguez","year":"2025","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105002_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","article-title":"Site-specific transgene integration in Chimeric Antigen Receptor (CAR) T cell therapies","volume":"11","author":"Dabiri","year":"2023","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105002_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/cancers10060194","article-title":"TGF-\u03b2 in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105002_bib27","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41375-020-0719-y","article-title":"Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells","volume":"34","author":"Danylesko","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105002_bib28","first-page":"5390","article-title":"Type 3 innate lymphoid cells promote acute myeloid leukemia immune evasion and expansion","volume":"142","author":"Dinh","year":"2023"},{"key":"10.1016\/j.critrevonc.2025.105002_bib29","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2022.068","article-title":"Secretion of 4-1BB ligand crosslinked to PD-1 checkpoint inhibitor potentiates chimeric antigen receptor T cell solid tumor efficacy","author":"Dunn","year":"2023","journal-title":"Human Gene Therapy 34 (2122) 114561"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2023-190073","article-title":"Engineered natural killer cells expressing Chimeric Ilt Receptors (CIR) effectively target HLA-G positive AML tumor cells","volume":"142","author":"Duong","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib31","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2022-168877","article-title":"Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed\/refractory AML","volume":"140","author":"Ehninger","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300174","article-title":"Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager","volume":"19","author":"Eissenberg","year":"2024","journal-title":"PloS One"},{"issue":"7643","key":"10.1016\/j.critrevonc.2025.105002_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib34","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biology Blood Marrow Transplantation Journal American Society Blood Marrow Transplantation"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105002_bib35","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","article-title":"Proposed mechanism of Off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake","volume":"62","author":"Gorovits","year":"2013","journal-title":"Cancer Immunology Immunotherapy CII"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105002_bib37","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib38","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00277-024-05853-2","article-title":"Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT","volume":"103","author":"Guo","year":"2024","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105002_bib39","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-16-1904","article-title":"Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate, in acute myeloid leukemia","volume":"23","author":"Han","year":"2017","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105002_bib40","first-page":"1022","article-title":"Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors","volume":"7","author":"Heiblig","year":"2015","journal-title":"World J. Stem Cells"},{"issue":"June","key":"10.1016\/j.critrevonc.2025.105002_bib41","article-title":"Comparisons of long-term survival and safety of haploidentical hematopoietic stem cell transplantation after CAR-T cell therapy or chemotherapy in pediatric patients with first relapse of B-cell acute lymphoblastic leukemia based on MRD-guided treatment","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"issue":"June","key":"10.1016\/j.critrevonc.2025.105002_bib42","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory non-hodgkin\u2019s lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib43","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1182\/blood-2022-170712","article-title":"Off-the-shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"July","key":"10.1016\/j.critrevonc.2025.105002_bib45","volume":"142","author":"Indran","year":"2024","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor \u03b1 chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.stem.2021.02.013","article-title":"Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors","volume":"28","author":"Jones","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105002_bib51","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"6_ement","key":"10.1016\/j.critrevonc.2025.105002_bib52","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/1538-7445.AM2024-1333","article-title":"Abstract 1333: preclinical data supporting the phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML","volume":"84","author":"Kaveri","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105002_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front. Immunol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2023-186452","article-title":"HMGA1 chromatin regulators drive immune evasion in MPN progression through epigenetic rewiring to repress antigen presentation","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105002_bib55","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41375-024-02381-w","article-title":"A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia","volume":"38","author":"Koedijk","year":"2024","journal-title":"Leukemia"},{"issue":"1_ement","key":"10.1016\/j.critrevonc.2025.105002_bib56","doi-asserted-by":"crossref","first-page":"A019","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A019","article-title":"Abstract A019: prognostic significance of natural killer ligand expression in acute myeloid leukemia","volume":"4","author":"Koldej","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105002_bib57","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2025.105002_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899468","article-title":"Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia","volume":"13","author":"Kubicka","year":"2022","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105002_bib59","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in Acute Myeloid Leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib60","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1182\/blood-2024-207659","article-title":"The safety and efficacy of CD33 CAR-T therapy for RR AML after HSCT","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib61","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/1096-8652(200012)65:4<319::AID-AJH13>3.0.CO;2-1","article-title":"\u201cLineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: report of an adult case and review of the literature.\u201d","volume":"65","author":"Lounici","year":"2000","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105002_bib63","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib64","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers16050877","article-title":"Preclinical characterization of the anti-leukemia activity of the CD33\/CD16a\/NKG2D immune-modulating TriNKET\u00ae CC-96191","volume":"16","author":"Lunn-Halbert","year":"2024","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105002_bib65","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","article-title":"Off-the-Shelf CAR\u2013engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia","volume":"7","author":"Mansour","year":"2023","journal-title":"Blood Adv."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105002_bib66","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T Cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib67","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","article-title":"CD47 expression in acute myeloid leukemia varies according to genotype","volume":"108","author":"Marra","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s11658-023-00455-8","article-title":"Deletion of CD36 exhibits limited impact on normal hematopoiesis and the leukemia microenvironment","volume":"28","author":"Meng","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.critrevonc.2025.105002_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692800","article-title":"Macrophages in acute myeloid leukaemia: significant players in therapy resistance and patient outcomes","volume":"9","author":"Miari","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib70","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Molecular Therapy Journal American Society Gene Therapy"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105002_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cancers15205060","article-title":"Immunotherapy with monoclonal antibodies for acute myeloid leukemia: a work in progress","volume":"15","author":"Molica","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13543784.2023.2179482","article-title":"Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets","volume":"32","author":"Morse","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105002_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004446","article-title":"Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression","volume":"10","author":"Mueller","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105002_bib74","doi-asserted-by":"crossref","unstructured":"Muth, J.J., M.E. Mathyer, B. Cruz, et al. 2022. \u201cP1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R\/R) ACUTE MYELOID LEUKEMIA (AML).\u201d HemaSphere 6 (Suppl): 1309\u20131310. https:\/\/doi.org\/10.1097\/01.HS9.0000848560.56093.16.","DOI":"10.1097\/01.HS9.0000848560.56093.16"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib75","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2024-208795","article-title":"CD123-CAR T cells manufactured in the presence of dasatinib induce high grade CRS and\/or IEC-HS without improving efficacy in pediatric patients with recurrent\/refractory leukemia","volume":"144","author":"Naik","year":"2024","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib76","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1182\/blood-2023-184741","article-title":"T Cell\/natural killer (NK) cell transcriptional profiles are associated with response to gilteritinib in FLT3-mutated acute myeloid leukemia","volume":"142","author":"Nanni","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib78","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","article-title":"TGF-\u03b2: guardian of T cell function","volume":"191","author":"Oh","year":"2013","journal-title":"Journal Immunology (Baltimore Md. 1950)"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib79","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.21037\/tcr.2016.08.15","article-title":"Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy","volume":"5","author":"Perna","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib80","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40268-024-00491-5","article-title":"Trametinib sensitivity is defined by a myeloid differentiation profile in acute myeloid leukemia","volume":"24","author":"Quesnel-Valli\u00e8res","year":"2024","journal-title":"Drugs RD"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105002_bib82","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"30","author":"Rakhshandehroo","year":"2024","journal-title":"Nat. Biotechnol. Print. July"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib83","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Molecular Therapy Journal American Society Gene Therapy"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib84","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41409-020-01039-2","article-title":"Wilm\u2019s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation","volume":"56","author":"Rautenberg","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"2 Pt A","key":"10.1016\/j.critrevonc.2025.105002_bib85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14712598.2024.2384086","article-title":"Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies","volume":"24","author":"Reed","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105002_bib87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fimmu.2020.00311","article-title":"NK cell function regulation by TGF-\u03b2-induced epigenetic mechanisms","volume":"11","author":"Regis","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105002_bib88","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/1535-7163.MCT-20-1030","article-title":"Anti-CD19 CAR T cells that secrete a biparatopic anti-CLEC12A bridging protein have potent activity against highly aggressive acute myeloid leukemia in vitro and in vivo","volume":"20","author":"Rennert","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib89","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Molecular Therapy Journal American Society Gene Therapy"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib90","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/2767-9764.CRC-23-0402","article-title":"Single-cell CD4 and CD8 T-cell secretome profiling reveals temporal and niche differences in acute myeloid leukemia following immune checkpoint blockade therapy","volume":"4","author":"Root","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"December","key":"10.1016\/j.critrevonc.2025.105002_bib91","first-page":"9","article-title":"CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy","volume":"19","author":"Rosenberg","year":"2017","journal-title":"Curr. Opin. Chem. Eng."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105002_bib92","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.3390\/ijms24108953","article-title":"Acute myeloid leukemia causes serious and partially irreversible changes in secretomes of bone marrow multipotent mesenchymal stromal cells","volume":"24","author":"Sadovskaya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.critrevonc.2025.105002_bib93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","author":"Santomasso","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105002_bib94","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-024-02255-1","article-title":"AML\/T Cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","volume":"38","author":"Sayitoglu","year":"2024","journal-title":"Leukemia"},{"issue":"May","key":"10.1016\/j.critrevonc.2025.105002_bib95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2018.00152","article-title":"Therapeutic antibodies for myeloid neoplasms\u2014current developments and future directions","volume":"8","author":"Sch\u00fcrch","year":"2018","journal-title":"Front. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib96","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib97","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK Cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib98","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","article-title":"The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-024-01050-6","article-title":"Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody","volume":"14","author":"Stefa\u0144czyk","year":"2024","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105002_bib100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib101","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biomedicines10020307","article-title":"Enhanced chimeric antigen receptor T cell therapy through Co-application of synergistic combination partners","volume":"10","author":"Stock","year":"2022","journal-title":"Biomedicines"},{"issue":"S1","key":"10.1016\/j.critrevonc.2025.105002_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25428","article-title":"Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications","volume":"94","author":"Susanibar Adaniya","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105002_bib103","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib104","first-page":"15","article-title":"Immune therapy: a new therapy for acute myeloid leukemia","volume":"5","author":"Tian","year":"2023","journal-title":"Blood Science (Baltimore Md. )"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105002_bib106","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1038\/onc.2010.56","article-title":"Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5","volume":"29","author":"Walter","year":"2010","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105002_bib107","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14712598.2020.1817373","article-title":"Brief overview of antibody-drug conjugate therapy for acute leukemia","volume":"21","author":"Walter","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105002_bib108","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cbin.12225","article-title":"AML Cell-derived exosomes suppress the activation and cytotoxicity of NK cells in AML via PD-1\/PD-L1 pathway","volume":"48","author":"Wang","year":"2024","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105002_bib110","article-title":"Targeted therapy in NPM1-mutated AML: knowns and unknowns","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105002_bib111","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/jcm8081261","article-title":"Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats","volume":"8","author":"Williams","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2025.105002_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1374068","article-title":"STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance","volume":"15","author":"Witalisz-Siepracka","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-020-00941-y","article-title":"A single-cell survey of cellular hierarchy in acute myeloid leukemia","volume":"13","author":"Wu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib114","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"May","key":"10.1016\/j.critrevonc.2025.105002_bib115","article-title":"Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape","volume":"34","author":"Xie","year":"2023","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105002_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1230","article-title":"NKG2D and MICA\/B shedding: A \u2018Tag Game\u2019 between NK cells and malignant cells","volume":"9","author":"Xing","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3343\/alm.2023.43.1.86","article-title":"Improvement of Anti-CD36 antibody detection via monoclonal antibody immobilization of platelet antigens assay by using selected monoclonal antibodies","volume":"43","author":"Xu","year":"2023","journal-title":"Ann. Lab. Med."},{"issue":"8016","key":"10.1016\/j.critrevonc.2025.105002_bib118","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"issue":"December","key":"10.1016\/j.critrevonc.2025.105002_bib119","article-title":"Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib121","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/00045632231184716","article-title":"Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival","volume":"61","author":"You","year":"2024","journal-title":"Ann. Clin. Biochem."},{"issue":"37","key":"10.1016\/j.critrevonc.2025.105002_bib122","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030644","article-title":"Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): a systematic review and meta-analysis","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine"},{"issue":"7926","key":"10.1016\/j.critrevonc.2025.105002_bib123","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105002_bib124","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105002_bib125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2643-3230.BCD-19-0077","article-title":"Apolipoprotein C2 - CD36 promotes leukemia growth and presents a targetable axis in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib126","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105002_bib127","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2023-184477","article-title":"The modified melphalan-cladribine-busulfan-cyclophosphamide (mcbc) conditioning regimen improved relapse-free survival after Allo-HSCT in refractory\/relapsed AML","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105002_bib128","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20220647","article-title":"Inflammatory response mediates cross-talk with immune function and reveals clinical features in acute myeloid leukemia","volume":"42","author":"Zhong","year":"2022","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105002_bib130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-024-00983-2","article-title":"Genetics and pathologic landscape of lineage switch of acute leukemia during therapy","volume":"14","author":"Zhou","year":"2024","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105002_bib131","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cll.2021.04.005","article-title":"Antigen loss after targeted immunotherapy in hematological malignancies","volume":"41","author":"Zhou","year":"2021","journal-title":"Clin. Lab. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105002_bib132","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216796120","article-title":"O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation","volume":"120","author":"Zhu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:04:52Z","timestamp":1773828292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":132,"alternative-id":["S1040842825003907"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current progress in the elucidation of Acute Myeloid Leukemia (AML) immune landscapes","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105002"}}